• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
OSI-027

OSI-027

Product ID O7332
Cas No. 936890-98-1
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $82.00 In stock
5 mg $209.60 In stock
10 mg $355.30 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

OSI-027 is an inhibitor of mTORC1/2 that exhibits anticancer chemotherapeutic activity. In vitro, OSI0027 inhibits phosphorylation of downstream target Akt, inhibiting cell proliferation in breast cancer cells. OSI-027 also induces apoptosis in several lymphoid cell lines including mantle cell lymphoma, acute lymphocytic leukemia (ALL), and others. In animal models of cancer, this compound inhibits tumor growth.

Product Info

Cas No.

936890-98-1

Purity

≥99%

Formula

C21H22N6O3

Formula Wt.

406.44

IUPAC Name

4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid

Solubility

DMSO 18 mg/mL (44.28 mM) Water Insoluble Ethanol Insoluble

Appearance

Pale yellow powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

O7332 MSDS PDF

Info Sheet

O7332 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. PMID: 22476852.

Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12;119(2):476-87. PMID: 22080480.

Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83. PMID: 21363918.

Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 2010 Oct;6(7):966-7. PMID: 20699667.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R5661

    Ropinirole Hydrochloride

    Indoline; D2/3 agonist.

    ≥99%
  • S3476

    Sitagliptin Phosphate Monohydrate

    DPP4 inhibitor.

    ≥98%
  • P0252

    Pancuronium Bromide

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • Y0002

    Y-320

    Phenylpyrazoleanilide; IL-17 production inhibit...

    ≥98%
  • R3475

    Risperidone

    Benzisoxazole; 5-HT7 and NMDA agonist, D-amino ...

    ≥98%
  • G733409

    GSK-2982772

    RIP1 inhibitor.

    ≥98%
  • D3420

    4-(3,4-Difluorobenzo)curcumin

    Curcumin derivative.

    ≥95%
  • L5648

    Lomustine

    Nitrosourea, DNA alkylator.

    ≥98%
  • N1977

    Neurokinin A (4-10)

    Endogenous neuropeptide, also known as substanc...

    ≥95%
  • B1640

    Benzydamine Hydrochloride

    NSAID; PG synthetase inhibitor.

    ≥98%
  • O6805

    Orbifloxacin

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥99%
  • K624760

    KPT-276

    CRM1/XPO1 inhibitor.

    ≥99%
  • G5322

    GNF-5

    Abl inhibitor.

    ≥99%
  • A5070

    Angiotensin Acetate

    Peptide, derivative of AT I, cleavage product o...

    ≥95%
  • S1968

    Seratrodast

    TxA2 antagonist.

    ≥99%
  • P3540

    PIK-75 Hydrochloride

    p110α PI3K inhibitor.

    ≥98%
  • B6957

    Bromhexine Hydrochloride

    Synthetic derivative of vasicine, mucolytic.

    ≥98%
  • P0392

    Paxilline

    Neuroactive mycotoxin produced by Penicillum an...

    ≥98%
  • C4656

    Clopidol

    Coccidiostat.

    ≥98%
  • T1733

    Teicoplanin

    Glycopeptide, vancomycin analog; peptidoglycan ...

    ≥900 ug/mg, bio assay

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only